MedTrace Logo

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

NCT00089674 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1468

Last updated 2018-10-17

Study results available
· View outcomes & findings →

Summary

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Conditions

Interventions

DRUG

AMG 162

60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

DRUG

Placebo

60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-01
Primary Completion
2008-05-16
Completion
2010-05-11

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089674 on ClinicalTrials.gov